ZIMLAB137.20

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹734 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation16.020.120.0
+ Finance Costs6.911.413.2
+ Interest Income-0.0-0.1-0.3
+ Dividend Income0.00.0-0.0
+ Share-based Payments0.01.41.1
+ Unrealised FX (Gain) / Loss-1.1-0.3-2.8
+ Other Non-cash Items-0.2-0.7-0.2
+ Other Reconciling Items0.50.6-1.8
Changes in Working Capital
+ Inventories-27.6-5.2-7.3
+ Trade Receivables — Current-4.7-8.01.1
+ Other Financial Assets — Current-1.3-0.75.8
+ Other Financial Assets — Non-current-0.7-0.1-0.0
+ Other Non-current Assets-0.4-0.10.2
+ Trade Payables — Current4.17.13.4
+ Other Financial Liabilities — Current-1.52.7-0.3
+ Other Non-current Liabilities5.3-6.113.0
Cash from Operating Activities
Profit Before Tax (per I/S)23.618.08.25.1
+ Total Adjustments (incl. Working Capital)-4.822.145.1
Cash from Operations (pre-tax)18.940.153.3
+ Income Taxes Paid2.6-1.13.7
Cash from Operating Activities16.341.249.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)73.940.844.4
+ Disp of Fixed Assets0.50.75.6
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing0.00.00.2
+ Other Inflows / (Outflows) — Investing0.30.1-17.8
Cash from Investing Activities-73.0-39.9-56.3
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.035.0
+ Proceeds from Exercise of Stock Options0.00.00.1
+ Proceeds from Borrowings28.124.624.8
+ Repayment of Borrowings-19.217.814.7
+ Payment of Lease Liabilities1.73.63.9
+ Interest Paid7.512.312.9
+ Other Inflows / (Outflows) — Financing21.40.0-0.2
Cash from Financing Activities59.5-9.128.2
Net Changes in Cash (pre-FX)2.8-7.921.4
+ Effect of FX Rate Changes on Cash0.40.21.8
Net Changes in Cash3.2-7.723.2
Closing Cash9.6
Reference Items
EBITDA41.343.730.028.2
EBITDA Margin %11.2511.548.027.11
Free Cash Flow (CFO − Capex)-57.60.45.15.1
Free Cash Flow to Equity-6.13.1
Free Cash Flow per Basic Share-10.770.070.960.96
Price to Free Cash Flow142.60
Cash Flow to Net Income0.943.388.48
Cash Paid for Taxes2.6-1.13.7
Cash Paid for Interest7.512.312.9
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.